Bone Therapeutics

59 articles about Bone Therapeutics

• Bone Therapeutics Completes Recruitment Of Its ALLOB Phase IIA Spinal Fusion Study

  5/3/2016

• Bone Therapeutics Reports Initial Efficacy Results From Its PREOB Phase IIA Trial In Severe Osteoporosis

  3/29/2016

• Bone Therapeutics Reports Full Year 2015 Results

  3/29/2016

• Bone Therapeutics Notice Of Full Year 2015 Results

  3/16/2016

• Bone Therapeutics Presents ALLOB Pre-Clinical And Early Clinical Efficacy Data In Spinal Fusion At The "Clinical Applications Of Stem Cells" Conference

  2/24/2016

• Bone Therapeutics Treats 12 Patients Without Safety Concerns In ALLOB Phase IIA Spinal Fusion Trial

  2/17/2016

• Bone Therapeutics Announces Its Financial Calendar For 2016

  12/23/2015

• Bone Therapeutics Treats First Patients In ALLOB Phase IIA Spinal Fusion Trial

  3/23/2015

• Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial

  1/19/2015

• Bone Therapeutics Release: €1 Million Funding Secured From The Walloon Region To Investigate These Innovative Products For The Treatment Of Large Bone Defects

  1/5/2015

• Bone Therapeutics Confirms Safety In ALLOB® Phase 1/2a Trial For Delayed-Union Fractures

  12/16/2014

• Bone Therapeutics Appoints Dr. Guy Heynen As Chief Clinical And Regulatory Officer

  11/24/2014

• Bone Therapeutics & Kasios Collaborate On Novel Product For Optimisation Of Spinal Fusion Procedures

  11/17/2014

• Bone Therapeutics Extends ALLOB® Phase I/IIa Trial To Germany

  10/9/2014

• Bone Therapeutics: First Ever Clinical Trial - Allogeneic Bone Cell Therapy Product

  7/17/2014

• Bone Therapeutics Starts Patient Treatment In First Ever Clinical Trial With Allogeneic Bone Cell Therapy Product

  6/25/2014

• Bone Therapeutics And Partners Awarded Highly Competitive €3.8 Million Marie Curie Research Grant

  12/17/2013

• Bone Therapeutics Treats First Patients In PREOB® Pivotal Phase IIb/III Trial For The Treatment Of Non-Union Fractures

  11/26/2013

• Bone Therapeutics' Pivotal Phase III Osteonecrosis Trial With PREOB® hits a New Milestone

  11/7/2013